ATE237694T1 - Adenovirus vermittelter gentransfer in den gastrointestinaltrakt - Google Patents

Adenovirus vermittelter gentransfer in den gastrointestinaltrakt

Info

Publication number
ATE237694T1
ATE237694T1 AT92918712T AT92918712T ATE237694T1 AT E237694 T1 ATE237694 T1 AT E237694T1 AT 92918712 T AT92918712 T AT 92918712T AT 92918712 T AT92918712 T AT 92918712T AT E237694 T1 ATE237694 T1 AT E237694T1
Authority
AT
Austria
Prior art keywords
gastrointestinal tract
adenovirus
gene transfer
mediated gene
relates
Prior art date
Application number
AT92918712T
Other languages
English (en)
Inventor
Ronald G Crystal
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE237694T1 publication Critical patent/ATE237694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92918712T 1991-08-20 1992-08-20 Adenovirus vermittelter gentransfer in den gastrointestinaltrakt ATE237694T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74737191A 1991-08-20 1991-08-20
PCT/US1992/007029 WO1993003769A1 (en) 1991-08-20 1992-08-20 Adenovirus mediated transfer of genes to the gastrointestinal tract

Publications (1)

Publication Number Publication Date
ATE237694T1 true ATE237694T1 (de) 2003-05-15

Family

ID=25004780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92918712T ATE237694T1 (de) 1991-08-20 1992-08-20 Adenovirus vermittelter gentransfer in den gastrointestinaltrakt

Country Status (9)

Country Link
EP (1) EP0648271B1 (de)
JP (1) JP3534749B2 (de)
AT (1) ATE237694T1 (de)
AU (1) AU663725B2 (de)
CA (1) CA2115742A1 (de)
DE (1) DE69233013T2 (de)
DK (1) DK0648271T3 (de)
ES (1) ES2197145T3 (de)
WO (1) WO1993003769A1 (de)

Families Citing this family (492)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0560932T3 (de) * 1990-12-04 1997-02-17 Univ Texas
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
AU663702B2 (en) * 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
JPH07506370A (ja) * 1992-05-01 1995-07-13 アメリカ合衆国 バイスタンダー作用による殺腫瘍療法
AU680459B2 (en) * 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
JPH08509869A (ja) * 1993-05-10 1996-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 膵臓および胆管の上皮細胞への遺伝子導入
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH10507061A (ja) * 1994-04-28 1998-07-14 ザ ユニバーシティ オブ ミシガン アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
AU4743196A (en) * 1994-12-30 1996-07-24 Chiron Corporation Non-traumatic administration of gene delivery vehicles
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
FR2732978B1 (fr) * 1995-04-14 1997-05-30 Inst Nat Sante Rech Med Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
KR19990022184A (ko) * 1995-06-07 1999-03-25 스톤 스티븐 에프. 유전자구성물의 경구투여
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2250222A1 (en) 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
JP4399112B2 (ja) 1998-01-14 2010-01-13 カイロン ソチエタ ア レスポンサビリタ リミタータ ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP2261357A3 (de) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
JP2002533124A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
JP5138851B2 (ja) 1999-06-28 2013-02-06 オクラホマ メディカル リサーチ ファウンデーション 触媒的に活性な組換えメマプシンおよびその使用方法
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US6410236B1 (en) 1999-09-01 2002-06-25 The Regents Of The University Of Michigan Correcting diastolic dysfunction in heart failure
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
US8273360B2 (en) 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
EP1854476A3 (de) 2000-02-09 2008-05-07 Bas Medical, Inc. Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
MXPA02008279A (es) 2000-02-23 2002-11-29 Smithkline Beecham Biolog Proteinas animales especificas de tumor.
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1370684B1 (de) 2000-06-15 2008-05-28 Novartis Vaccines and Diagnostics, Inc. Polynukleotide zur bestimmung von kolonkrebs
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
AU2001270252B2 (en) 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
EP2277894A1 (de) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nukleinsäure und Proteine von Gruppen A und B Streptokokken
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
JP2005502591A (ja) 2001-01-12 2005-01-27 カイロン コーポレイション 核酸粘膜免疫
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2452119C (en) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003039491A2 (en) 2001-11-09 2003-05-15 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
IL162077A0 (en) 2001-11-21 2005-11-20 Univ Leland Stanford Junior Polynucleotide therapy the board of trustees of the leland stanford junior university
WO2003049762A2 (en) 2001-12-12 2003-06-19 Chiron Srl. Immunisation against chlamydia trachomatis
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
JP4376629B2 (ja) 2002-01-08 2009-12-02 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
KR100981471B1 (ko) 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의ｐ4 변형 단백질
CA2479730A1 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
JP2005535308A (ja) 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
CN101955976A (zh) 2002-11-21 2011-01-26 贝希尔治疗学股份有限公司 预防和治疗疾病的方法及免疫调节核酸组合物
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EA011479B1 (ru) 2002-12-24 2009-04-28 Ринат Ньюросайенс Корп. Антитело связывающееся с ngf, и способы его применения
EP2940028B8 (de) 2003-01-06 2017-09-27 Corixa Corporation Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
CA2516138A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
HRP20050721A2 (en) 2003-02-19 2007-03-31 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
JP2006524057A (ja) 2003-04-21 2006-10-26 エペイウス バイオテクノロジーズ， インコーポレイテッド 疾患を処置するための方法および組成物
EP1628680B1 (de) 2003-05-15 2012-10-24 Novartis Vaccines and Diagnostics, Inc. Hiv polynucleotide und polypeptide von botswana mj4
EP1625210B1 (de) 2003-05-21 2010-12-01 Genzyme Corporation Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20050036988A1 (en) * 2003-05-28 2005-02-17 Ruian Xu Compositions and methods for preventing and treating liver cirrhosis
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
CN1957082B (zh) 2004-03-29 2014-09-17 株式会社嘉尔药物 新的半乳凝素9突变体蛋白质及其用途
MXPA06011463A (es) 2004-04-07 2007-04-25 Rinat Neuroscience Corp Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio.
EP3381930B1 (de) 2004-07-09 2025-04-16 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Lösliche formen von hendra- und nipah-virus-g-glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP2298807A3 (de) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Gegen das Amyloid-beta-Peptid gerichtete Antikörper und Verfahren zu deren Anwendung
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
WO2006020996A2 (en) 2004-08-11 2006-02-23 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
EP2338524B1 (de) 2004-08-12 2013-05-22 Cedars-Sinai Medical Center Kombinierte Gentherapie zur Behandlung makroskopischer Glioma
EP2893938B1 (de) 2004-09-22 2019-03-06 GlaxoSmithKline Biologicals SA Immunogene Zusammensetzung zur Verwendung als Impfstoff gegen Staphylokokken
CN102626336A (zh) 2004-10-05 2012-08-08 建新公司 台阶式插管
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
EP2062591A1 (de) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E in der Krebsdiagnose-Erkennung und -Behandlung
JP2008535494A (ja) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド 癌関連遺伝子（ｐｒｌｒ）
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP2816118B1 (de) 2005-05-31 2018-10-17 The Regents of the University of Colorado, a body corporate Verfahren zur Bereitstellung von Genen
RU2486204C2 (ru) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
US7858590B2 (en) 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
EP1979488A4 (de) 2006-01-09 2009-05-27 Univ California Immunstimulierende kombinationen aus tnfrsf, tlr, nlr, rhr, purinergischem rezeptor, und zytokin-rezeptor-antaonisten für impfstoffe und die tumorimmuntherapie
CA2648086C (en) 2006-03-29 2014-05-13 Dana Farber Cancer Institute, Inc. Methods and compositions for inducing an immune response to hiv and models for testing
CN102164618A (zh) 2006-03-30 2011-08-24 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
WO2007146172A2 (en) 2006-06-07 2007-12-21 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
US8685720B2 (en) 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
CN1966082B (zh) * 2006-11-03 2010-06-30 许瑞安 一种防治结直肠癌的基因药物及其制备方法和用途
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
WO2008124176A2 (en) 2007-04-10 2008-10-16 The Administrators Of The Tulane Educational Fund Soluble and membrane-anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR20130087632A (ko) 2007-12-17 2013-08-06 화이자 리미티드 간질성 방광염의 치료
RU2528738C2 (ru) 2007-12-18 2014-09-20 Биоэллаенс К.В. Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
CA2718975A1 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TR201815802T4 (tr) 2008-06-25 2018-11-21 Mesoblast Inc İnvertabral disklerin onarılması ve/veya yeniden yapılandırılması.
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
CN104546912B (zh) 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
EP2391388A1 (de) 2009-01-29 2011-12-07 University of California-San Francisco Verfahren zur verteilung von hohen konzentrationen eines therapeutischen mittels durch die kortex zur behandlung von neurologischen erkrankungen
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
ES2565377T3 (es) 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus
BRPI1010868A2 (pt) 2009-05-02 2018-06-12 Genzyme Corp terapia gênica para distúrbios neurodegenerativos
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
PT2464658E (pt) 2009-07-16 2015-01-14 Novartis Ag Imunogénios de escherichia coli desintoxicados
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
TWI596114B (zh) 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
EP2563907B1 (de) 2010-04-28 2019-06-19 The J. David Gladstone Institutes Verfahren zur erzeugung von kardiomyozyten
WO2011143124A2 (en) 2010-05-10 2011-11-17 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
WO2011154553A2 (en) 2010-06-11 2011-12-15 Cellartis Ab Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
AU2011274255B2 (en) 2010-07-02 2016-05-05 Mesoblast, Inc. Treatment of T-cell mediated immune disorders
EP2598126A2 (de) 2010-07-30 2013-06-05 Saint Louis University Verfahren zur behandlung von schmerz
WO2012049314A1 (en) 2010-10-15 2012-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24 -hydrolase in therapy of huntington' s disease
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2663868A2 (de) 2010-12-01 2013-11-20 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen zur abzielung auf neovaskuläre wachstumsstellen
ES2716015T3 (es) 2011-06-03 2019-06-07 Mesoblast Inc Procedimiento para tratar los efectos de un accidente cerebrovascular
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
ES3013463T3 (en) 2011-07-04 2025-04-14 Mesoblast Inc Treating or preventing rheumatic disease
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
WO2013033777A1 (en) 2011-09-09 2013-03-14 Mesoblast, Inc Methods for increasing osteoblastic function
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
CA3036859A1 (en) 2011-12-16 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
WO2013176772A1 (en) 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
EP3685854A1 (de) 2012-08-16 2020-07-29 Ipierian, Inc. Verfahren zur behandlung einer tauopathie
EP2912065A4 (de) 2012-10-25 2016-10-19 True North Therapeutics Inc Anti-komplement-c1s-antikörper und verwendungen davon
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
WO2014072876A1 (en) 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
SG10201706671WA (en) 2012-11-30 2017-09-28 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
ES2742035T3 (es) 2012-12-12 2020-02-12 Mesoblast Inc Tratamiento de las enfermedades de la disfunción y la inflamación endotelial
DK2943567T3 (en) 2013-01-08 2018-01-02 Genzyme Corp USE OF INOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
EP2956557B1 (de) 2013-02-14 2018-07-11 The J. David Gladstone Institutes Zusammensetzungen und verfahren zur verwendung davon zur identifizierung von viruziden
PT3300745T (pt) 2013-02-15 2019-11-27 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
WO2014153258A2 (en) 2013-03-14 2014-09-25 Epeius Biotechnologies Corporation Improved thymidine kinase gene
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
US9644215B2 (en) 2013-04-12 2017-05-09 The General Hospital Corporation AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
WO2014172560A1 (en) 2013-04-17 2014-10-23 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
HK1218421A1 (zh) 2013-05-07 2017-02-17 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
CA2914768A1 (en) 2013-06-10 2014-12-18 Ipierian, Inc. Methods of treating a tauopathy
US10220053B2 (en) 2013-06-25 2019-03-05 University Of Canberra Methods and compositions for modulating cancer stem cells
EP3044314B1 (de) 2013-07-12 2019-04-10 SeNa Research, Inc. Verfahren und zusammensetzungen zur interferenz mit dna-polymerase und dna-synthese
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
BR112016002008B1 (pt) 2013-08-02 2021-06-22 Pfizer Inc. Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
EP3039129B1 (de) 2013-08-30 2018-06-27 Amgen Inc. Herstellung rekombinanter aav-vektoren mit hohem titer in haftenden und hängenden zellen
EP3046560B1 (de) 2013-09-18 2021-01-06 EpiAxis Therapeutics Pty Ltd Stammzellenmodulation ii
WO2015067668A1 (en) 2013-11-05 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) New alzheimer's disease animal model
BR112016009797A2 (pt) 2013-11-13 2017-12-05 Bristol Myers Squibb Co anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
AU2014350051A1 (en) 2013-11-18 2016-07-07 Crispr Therapeutics Ag CRISPR-Cas system materials and methods
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3080266B1 (de) 2013-12-12 2021-02-03 The Regents of The University of California Verfahren und zusammensetzungen zur modifizierung einer einzelsträngigen zielnukleinsäure
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
CN111068072A (zh) 2014-02-06 2020-04-28 建新公司 用于治疗和预防黄斑变性的组合物及方法
WO2015124546A1 (en) 2014-02-19 2015-08-27 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic Aav vectors for the treatment of ischemic and non-ischemic heart disease
KR102417915B1 (ko) 2014-03-21 2022-07-07 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴클레아제 없는 게놈 편집
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3139955B1 (de) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusionsproteine zur behandlung von krebs und zugehörige verfahren
CN106459960A (zh) 2014-05-13 2017-02-22 生物蛋白有限公司 条件活性生物蛋白
SG10202006338UA (en) 2014-06-18 2020-08-28 Albert Einstein College Medicine Inc Syntac polypeptides and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
KR102818922B1 (ko) 2014-08-28 2025-06-11 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
CA2959786A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3233130T3 (da) 2014-12-17 2021-06-21 Fundacion Para La Investig Medica Aplicada Nukleinsyrekonstruktioner og genterapivektorer til anvendelse i behandlingen af wilson-sygdom
PT3233129T (pt) 2014-12-17 2020-04-15 Fundacion Para La Investig Medica Aplicada Construções de ácido nucleico e vetores de terapia génica para utilização no tratamento de doença de wilson e outras condições
NZ771568A (en) 2015-01-02 2024-11-29 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
EP3054006A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
EP3054007A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
EP3858992A1 (de) 2015-03-13 2021-08-04 The Jackson Laboratory Dreikomponentiges crispr/cas-komplexsystem und verwendungen davon
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
US11040113B2 (en) 2015-03-23 2021-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
CN107532177A (zh) 2015-03-24 2018-01-02 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
HK1259251A1 (zh) 2015-04-06 2019-11-29 Bioverativ Usa Inc. 人源化抗c1s抗体及其使用方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
EP3280425B1 (de) 2015-04-07 2022-06-01 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Verfahren zur induzierung von zellteilung von postmitotischen zellen
SG10201912823PA (en) 2015-04-13 2020-02-27 Pfizer Therapeutic antibodies and their uses
WO2016177805A1 (en) 2015-05-05 2016-11-10 Mesoblast International Sàrl Potency assay
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3303634B1 (de) 2015-06-03 2023-08-30 The Regents of The University of California Cas9-varianten und verfahren zur verwendung davon
EP3307391A1 (de) 2015-06-12 2018-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzung zur behandlung der alzheimer-krankheit
EP3313863B1 (de) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degronfusionskonstrukte und verfahren zur steuerung der proteinproduktion
ES2895652T3 (es) 2015-07-07 2022-02-22 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para expresar un polinucleótido de interés en el sistema nervioso periférico de un sujeto
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
KR102794955B1 (ko) 2015-07-21 2025-04-15 다케다 파머수티컬 컴패니 리미티드 Xiia 인자의 단일클론 항체 저해제
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
EP3331536A4 (de) 2015-08-03 2019-03-27 The Regents of The University of California Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
CN113896789A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
WO2017064546A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
EP3362472B1 (de) 2015-10-16 2023-08-30 The Trustees of Columbia University in the City of New York Zusammensetzungen und verfahren zur hemmung von zelllinienspezifischen antigenen
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
US10669320B2 (en) 2015-11-18 2020-06-02 The Regents Of The University Of Michigan Mps1 and KNL1 phosphorylation system
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
US10406244B2 (en) 2015-12-02 2019-09-10 The Board Of Trustees Of The Leland Stanford Junior University AAV vectors with expanded packaging capacity
EP3384034B1 (de) 2015-12-02 2020-07-08 The Board of Trustees of the Leland Stanford Junior University Neue rekombinante kapside des adeno-associated virus mit erhöhtem tropismus für menschliche skelett- muskulatur
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3399991A4 (de) 2016-01-08 2019-08-07 The Regents of The University of California Bedingt aktive heterodimere polypeptide und verfahren zur verwendung davon
ES2926977T3 (es) 2016-01-19 2022-10-31 Univ California Métodos para el tratamiento de la enfermedad de Danon y otros trastornos de autofagia
WO2017125831A1 (en) 2016-01-21 2017-07-27 Pfizer Inc. Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
EP3417055B1 (de) 2016-02-16 2021-10-13 The Board of Trustees of the Leland Stanford Junior University Gegen vorhandene humane neuartige antikörper resistente, neuartige rekombinante adeno-assoziierte virus-kapside
US20190046648A1 (en) 2016-03-03 2019-02-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
WO2018161064A1 (en) 2017-03-03 2018-09-07 F1 Oncology, Inc. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
RU2755059C2 (ru) 2016-03-19 2021-09-13 Эксума Биотек Корп. Способы и составы для производства лимфоцитов и их регулируемого увеличения
SG11201808354PA (en) 2016-03-31 2018-10-30 Spark Therapeutics Inc Column-based fully scalable raav manufacturing process
IL295288B2 (en) 2016-04-04 2024-08-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
WO2017197234A1 (en) 2016-05-13 2017-11-16 Bioatla, Llc Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR20190044029A (ko) 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3028682A1 (en) 2016-06-20 2017-12-28 Howard Y. Chang Circular rnas and their use in immunomodulation
CA3030003A1 (en) 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
AU2017327384B2 (en) 2016-09-13 2021-05-20 The Jackson Laboratory Targeted enhanced DNA demethylation
WO2018057648A1 (en) 2016-09-20 2018-03-29 The Board Of Trustees Of The Leland Stanford Junior University Peptide regulators of mitochondrial fusion and methods of use
EP3525583B8 (de) 2016-10-12 2025-09-10 Bioverativ USA Inc. Anti-cs1-antikörper und verfahren zur verwendung davon
WO2018080573A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US12178845B2 (en) 2016-12-07 2024-12-31 The General Hospital Corporation Methods and compositions relating to the treatment of tumors
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
EP3565829A4 (de) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
SG10202107808SA (en) 2017-01-18 2021-08-30 F1 Oncology Inc Chimeric antigen receptors against axl or ror2 and methods of use thereof
WO2018136566A1 (en) 2017-01-18 2018-07-26 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
WO2018138360A1 (en) 2017-01-28 2018-08-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Oxygen carrying blood substitutes and their use as delivery vehicles
FI3574091T3 (fi) 2017-01-30 2023-05-03 Brainvectis Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
US20190359678A1 (en) 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
SG11201907835YA (en) 2017-03-03 2019-09-27 Rinat Neuroscience Corp Anti-gitr antibodies and methods of use thereof
EP3596206A1 (de) 2017-03-16 2020-01-22 Pfizer Inc Tyrosinprototrophie
EP3600267A1 (de) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur behandlung von neurodegenerativer krankheit
AU2018246143B2 (en) 2017-03-28 2025-06-05 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018195555A1 (en) 2017-04-21 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
AU2018262788B2 (en) 2017-05-04 2024-08-15 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
KR102396784B1 (ko) 2017-06-13 2022-05-13 보스턴진 코포레이션 분자 기능적 프로파일을 생성하고, 시각화하고, 분류하는 시스템 및 방법
WO2018232372A1 (en) 2017-06-16 2018-12-20 Protelica, Inc. Fibronectin binding domain chimeric antigen receptors and methods of use thereof
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
CN111315768A (zh) 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
AU2018334273B2 (en) 2017-09-15 2025-04-10 Brandeis University Multiplex production and barcoding of genetically engineered cells
US11970707B2 (en) 2017-09-18 2024-04-30 Children's Hospital Medical Center Strong insulator and uses thereof in gene delivery
CN112020648A (zh) 2017-10-04 2020-12-01 赫斯佩瑞克斯股份公司 针对癌症个体化疗法的制品和方法
WO2019075220A1 (en) 2017-10-11 2019-04-18 Bioverativ Usa Inc. METHODS FOR INDUCING COMPLEMENT ACTIVITY
US11266743B2 (en) 2017-10-25 2022-03-08 The Administrators Of The Tulane Educational Fund Peptide compositions and methods of use thereof
CN115261392B (zh) 2017-10-27 2025-05-13 纽约大学 抗半乳凝素-9抗体及其用途
EP3724332A1 (de) 2017-12-14 2020-10-21 CRISPR Therapeutics AG Neuartige rna-programmierbare endonukleasesysteme und deren verwendung in der genombearbeitung und anderen anwendungen
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
EP3743113A4 (de) 2018-01-23 2022-01-26 Southern Eye Equipment Expressionsvektor und verfahren
PE20251579A1 (es) 2018-02-01 2025-06-16 Pfizer Anticuerpos especificos para cd70 y sus usos
IL276396B1 (en) 2018-02-01 2025-09-01 Pfizer Chimeric antigen receptors against CD70
PE20201342A1 (es) 2018-02-28 2020-11-25 Pfizer Variantes de il-15 y usos de las mismas
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
EP3765064A1 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pcsk2-abgeleitete antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
WO2019175380A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765053A2 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigene peptide aus urocortin 3 und verwendungen davon zur diagnose und behandlung von typ-1-diabetes
EP3768834B1 (de) 2018-03-19 2025-08-13 CRISPR Therapeutics AG Neuartige rna-programmierbare endonukleasesysteme und deren verwendung in der genombearbeitung und in anderen anwendungen
WO2019191114A1 (en) 2018-03-27 2019-10-03 The Trustees Of The University Of Pennsylvania Modified immune cells having enhanced function and methods for screening for same
EP3774853A1 (de) 2018-03-30 2021-02-17 The Board of Trustees of the Leland Stanford Junior University Neuartige kapside des rekombinanten adeno-assoziierten virus mit erhöhtem menschlichem pankreatischem tropismus
EP3773633A4 (de) 2018-04-06 2022-01-26 The Regents of The University of California Verfahren zur behandlung von glioblastomen
WO2019195586A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
WO2019210325A1 (en) 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Gene therapy for cns degeneration
US20210180084A1 (en) 2018-05-14 2021-06-17 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
US12343397B2 (en) 2018-05-17 2025-07-01 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
SG11202010580TA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for cd3 and uses thereof
CA3100829A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
JP2021529559A (ja) 2018-07-03 2021-11-04 ソティオ，リミティド ライアビリティ カンパニー グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用
SG11202100022SA (en) 2018-07-12 2021-01-28 Rocket Pharmaceuticals Ltd Gene therapy vectors for treatment of danon disease
WO2020018166A1 (en) 2018-07-16 2020-01-23 The Regents Of The University Of Michigan Nuclease-mediated nucleic acid modification
CN112672790A (zh) 2018-08-09 2021-04-16 马弗里克治疗公司 条件性活化的结合蛋白的共表达和纯化方法
MX2021001771A (es) 2018-08-14 2021-07-16 Sotio Llc Polipéptidos del receptor de antígeno quimérico en combinación con moléculas del metabolismo trans que modulan el ciclo de krebs y usos terapéuticos de los mismos.
WO2020041456A1 (en) 2018-08-22 2020-02-27 The Regents Of The University Of California Variant type v crispr/cas effector polypeptides and methods of use thereof
AU2019333104A1 (en) 2018-08-28 2021-03-25 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2020047467A2 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
EP3863682B1 (de) 2018-10-12 2023-05-17 Vivet Therapeutics Codon-optimiertes transgen für die behandlung von progressiver familien intrahepatischer cholestase typ 3 (pfic3)
EP3827016B1 (de) 2018-10-15 2025-12-03 Elixiron Immunotherapeutics (Hong Kong) Limited Antikörper gegen granulozytenmakrophagenkolonie-stimulierenden faktor und deren verwendungen
HUE060949T2 (hu) 2018-10-29 2023-04-28 Inst Nat Sante Rech Med Koleszterin 24-hidroláz expressziós vektor amiotrófiás laterálszklerózis kezelésében
MX2021005435A (es) 2018-11-07 2021-09-08 Vivet Therapeutics Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2).
WO2020097445A1 (en) 2018-11-09 2020-05-14 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
JP7564102B2 (ja) 2018-11-28 2024-10-08 クリスパー セラピューティクス アクチェンゲゼルシャフト ＬＮＰでの使用に最適化された、ＣＡＳ９をコードするｍＲＮＡ
CA3119799A1 (en) 2018-12-04 2020-06-11 Catalent Pharma Solutions, Llc Vectors for protein manufacture
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132190A1 (en) 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
JP2022515916A (ja) 2019-01-02 2022-02-22 メゾブラスト・インターナショナル・エスアーエールエル 腰痛を治療するための方法
AU2020204809A1 (en) 2019-01-03 2021-07-29 Mesoblast International Sàrl Method for improving visual acuity
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
AU2020231391A1 (en) 2019-03-05 2021-10-28 Takeda Pharmaceutical Company Limited Conditionally activated binding proteins containing Fc regions and moieties targeting tumor antigens
EP3935080A4 (de) 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
WO2020180501A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory antigen-presenting polypeptides and methods of use thereof
AU2020231380B2 (en) 2019-03-07 2025-07-17 The Regents Of The University Of California CRISPR-Cas effector polypeptides and methods of use thereof
SG11202109741VA (en) 2019-03-12 2021-10-28 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020193441A1 (en) 2019-03-22 2020-10-01 Université de Paris New inhibitors of lrrk2/pp1 interaction
KR20210148232A (ko) 2019-04-01 2021-12-07 테나야 테라퓨틱스, 인코포레이티드 조작된 캡시드를 갖는 아데노-연관 바이러스
MX2021012003A (es) 2019-04-02 2021-11-04 Kenjockety Biotechnology Inc Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
EP3972631B1 (de) 2019-05-21 2024-07-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Expressionsvektor für cholesterin-24-hydrolase in der therapie des rett-syndroms
CA3140964A1 (en) 2019-05-23 2020-11-26 Mesoblast International Sarl Functional recovery from cerebral infarction
CN114222818B (zh) 2019-07-02 2025-07-08 基础应用医学研究基金会 cPLA2e诱导剂及其用途
EP3994696B1 (de) 2019-07-03 2025-05-14 BostonGene Corporation Systeme und verfahren zur probenvorbereitung, probensequenzierung sowie sequenzierdatenbiaskorrektur und qualitätskontrolle
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US20240092935A1 (en) 2019-10-11 2024-03-21 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
MX2022004873A (es) 2019-10-23 2022-05-13 Cue Biopharma Inc Polipeptidos de tgf-?.
EP4061943A1 (de) 2019-11-19 2022-09-28 Institut National de la Santé et de la Recherche Médicale (INSERM) Antisense-oligonukleotide und deren verwendung zur behandlung von krebs
WO2021113736A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Single-domain antibody to chloramphenicol
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021154079A1 (en) 2020-01-29 2021-08-05 Rijksuniversiteit Groningen Means and methods for modulating lipid metabolism
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
BR112022017551A2 (pt) 2020-03-02 2022-11-16 Tenaya Therapeutics Inc Controle de vetor genético por micrornas expressos por cardiomiócito
WO2021188770A1 (en) 2020-03-18 2021-09-23 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021222148A2 (en) 2020-04-27 2021-11-04 4D Molecular Therapeutics Inc. Adeno-associated variants, formulations and methods for pulmonary delivery
EP4146688A1 (de) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Maskenpeptide und maskierte anti-ptk7-antikörper damit
CA3184802A1 (en) 2020-05-26 2021-12-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
JP7768902B2 (ja) 2020-06-04 2025-11-12 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
JP2023528662A (ja) 2020-06-09 2023-07-05 ジェネトン 拡張型心筋症の処置における使用のためのｃｉｌｐ－１阻害剤
JP2023528663A (ja) 2020-06-09 2023-07-05 ジェネトン 遺伝性拡張型心筋症の処置
JP2023528661A (ja) 2020-06-09 2023-07-05 ジェネトン 拡張型心筋症の処置における使用のためのｎｒｆ２活性化剤
WO2021257512A1 (en) 2020-06-15 2021-12-23 Academia Sinica Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
CA3177613A1 (en) 2020-07-10 2022-04-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating epilepsy
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
IL299890A (en) 2020-07-17 2023-03-01 Janssen Biotech Inc Anti-idiotypic antibodies against anti-KLK2 antibodies
JP2023535604A (ja) 2020-07-30 2023-08-18 ファイザー・インク 遺伝子複製を有する細胞およびその使用
CN116390773A (zh) 2020-08-06 2023-07-04 应用医学研究基金会 用于通过基因疗法治疗诸如阿尔茨海默病的Tau蛋白病的病毒颗粒
EP4192487A4 (de) 2020-08-07 2024-10-02 Spacecraft Seven, LLC Plakophilin-2 (pkp2) gentherapie unter verwendung eines aav vektors
WO2022032085A1 (en) 2020-08-07 2022-02-10 The Jackson Laboratory Targeted sequence insertion compositions and methods
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
US20230272433A1 (en) 2020-09-29 2023-08-31 Genethon Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof
WO2022074105A1 (en) 2020-10-09 2022-04-14 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
US12254961B2 (en) 2020-12-04 2025-03-18 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
JP2024504613A (ja) 2021-01-14 2024-02-01 センティ バイオサイエンシズ インコーポレイテッド 分泌性ペイロード調節
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
EP4330969A1 (de) 2021-04-29 2024-03-06 BostonGene Corporation Maschinenlerntechniken zur schätzung der tumorzellenexpression in komplexem tumorgewebe
IL309179A (en) 2021-06-10 2024-02-01 Janssen Biotech Inc Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses
US20240141312A1 (en) 2021-06-11 2024-05-02 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
EP4101928A1 (de) 2021-06-11 2022-12-14 Bayer AG Programmierbare typ-v-rna-endonukleasesysteme
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
US20250084420A1 (en) 2021-08-02 2025-03-13 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
EP4144841A1 (de) 2021-09-07 2023-03-08 Bayer AG Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
KR20240069799A (ko) 2021-09-27 2024-05-20 소티오 바이오테크 인크. 해당과정 경로 밖으로 포도당 대사산물을 재지향시키는 트랜스 대사 분자와 조합되는 키메라 수용체 폴리펩타이드 및 이의 치료적 용도
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
US20240417434A1 (en) 2021-10-28 2024-12-19 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
EP4426832A1 (de) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Genaue genomeditierung mit retrons
JP2024545363A (ja) 2021-11-16 2024-12-05 ソティオ・バイオテック・インコーポレイテッド 粘液型／円形細胞型脂肪肉腫患者の治療
WO2023091954A2 (en) 2021-11-19 2023-05-25 The Trustees Of The University Of Pennsylvania Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy
CA3239461A1 (en) 2021-11-30 2023-06-08 Yvonne CHAN Human metapneumovirus viral vector-based vaccines
AU2022413942A1 (en) 2021-12-13 2024-05-30 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
US20250084391A1 (en) 2021-12-23 2025-03-13 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
JP2025505410A (ja) 2022-01-31 2025-02-26 ボストンジーン コーポレイション サイトメトリーのための機械学習法
CA3250331A1 (en) 2022-02-01 2023-08-10 Cornell University METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHY ASSOCIATED WITH FRIEDREICH'S ATAXIA
EP4473096A1 (de) 2022-02-02 2024-12-11 Pfizer Inc. Cysteinprototrophie
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
EP4469586A1 (de) 2022-03-01 2024-12-04 Exuma Biotech Corp. Viruspartikel mit membrangebundener hyaluronidase
CA3246348A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone RT-DNA AND RETRONS FIDELITY GENOMIC EDITING
US20250223586A1 (en) 2022-03-25 2025-07-10 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Methods of assessing engineered retron activity, and uses thereof
EP4499849A1 (de) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Herstellung von reverse transkribierter dna (rt-dna) unter verwendung einer retron reversen transkriptase aus exogener rna
AU2023284048A1 (en) 2022-06-10 2024-11-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
EP4299739A1 (de) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Zusammensetzungen und verfahren zur genomeditierung
WO2024005863A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
EP4299733A1 (de) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Zusammensetzungen, systeme und verfahren zum genomeditieren
WO2024005864A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
IL317719A (en) 2022-07-08 2025-02-01 Univ Cornell Methods and pharmaceutical compositions for the treatment and prevention of Alzheimer's disease
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
MA71557A (fr) 2022-07-18 2025-05-30 Renagade Therapeutics Management Inc. Composants d'édition génique, systèmes et procédés d'utilisation
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
EP4572787A1 (de) 2022-08-19 2025-06-25 SOTIO Biotech Inc. Genetisch veränderte immunzellen mit chimären rezeptorpolypeptiden in kombination mit mehreren transmetabolismusmolekülen und therapeutische verwendungen davon
WO2024044659A1 (en) 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
US20250243516A1 (en) 2022-08-24 2025-07-31 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Dual Cut Retron Editors for Genomic Insertions and Deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2024079317A1 (en) 2022-10-14 2024-04-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies
EP4599057A1 (de) 2022-11-09 2025-08-13 The Regents of University of California Hochdurchsatzentdeckung von mehrteiligen crispr-basierten editoren
CN120769907A (zh) 2022-11-18 2025-10-10 京都府公立大学法人 用于线粒体自噬诱导的组合物及其用途
CN120752335A (zh) 2022-12-13 2025-10-03 拜耳公司 工程化v型rna可编程核酸内切酶及其用途
WO2024146935A1 (en) 2023-01-06 2024-07-11 Institut National de la Santé et de la Recherche Médicale Intravenous administration of antisense oligonucleotides for the treatment of pain
AU2024218970A1 (en) 2023-02-06 2025-07-31 Bluerock Therapeutics Lp Degron fusion proteins and methods of production and use thereof
EP4669330A1 (de) 2023-02-21 2025-12-31 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung des sanfilippo-syndroms vom typ iiib
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
KR20250164239A (ko) 2023-03-15 2025-11-24 교토후고리츠다이가쿠호진 펩티드 발현 구축물 및 그의 용도
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
AU2024258754A1 (en) 2023-04-18 2025-11-13 Cornell University Methods and apoe pharmaceutical compositions for the treatment and the prevention of alzheimers disease
WO2024220719A1 (en) 2023-04-18 2024-10-24 Crystal Ronald G Modified aav capsids for gene delivery
WO2024220722A1 (en) 2023-04-18 2024-10-24 Cornell University Compositions and methods for tissue- specific expression of gene therapies
GB202307563D0 (en) 2023-05-19 2023-07-05 Univ King Abdullah Sci & Tech Methods and compositions
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
AU2024310260A1 (en) 2023-06-29 2025-12-11 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025051758A1 (en) 2023-09-04 2025-03-13 Splicebio, Sl Use of split intein for the treatment of scn1a associated disease
TW202521691A (zh) 2023-10-06 2025-06-01 美商藍岩醫療公司 經工程化之v型rna可程式核酸內切酶及其用途
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025096811A1 (en) 2023-10-31 2025-05-08 Bostongene Corporation Machine learning technique for identifying ici responders and non-responders
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
EP4563586A1 (de) 2023-11-28 2025-06-04 Université Paris Cité Neue inhibitoren der lrrk2/pp1-interaktion
WO2025114512A1 (en) 2023-11-29 2025-06-05 Cnrs Dsi Therapeutic use of surf2 modulators
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025153705A1 (en) 2024-01-18 2025-07-24 Splicebio, Sl Use of split intein for the treatment of myo7a-associated disease
WO2025157848A1 (en) 2024-01-23 2025-07-31 Institut National de la Santé et de la Recherche Médicale Methods for the intravenous treatment of sanfilippo syndrome type iiib
US20250253011A1 (en) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells

Also Published As

Publication number Publication date
DE69233013T2 (de) 2004-03-04
EP0648271B1 (de) 2003-04-16
AU2500692A (en) 1993-03-16
JPH06510665A (ja) 1994-12-01
AU663725B2 (en) 1995-10-19
EP0648271A1 (de) 1995-04-19
JP3534749B2 (ja) 2004-06-07
DK0648271T3 (da) 2003-07-21
WO1993003769A1 (en) 1993-03-04
CA2115742A1 (en) 1993-03-04
ES2197145T3 (es) 2004-01-01
DE69233013D1 (de) 2003-05-22
EP0648271A4 (de) 1994-11-25

Similar Documents

Publication Publication Date Title
ATE237694T1 (de) Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
FI971613A7 (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
NO961639L (no) Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
FI954966L (fi) Puutteellisia yhdistelmä-DNA-adenoviruksia kasvainten geeniterapiassa
ATE332363T1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
DK1046711T3 (da) Rekombinant adenoforbundet virus
EP1501863A4 (de) Kinaseankerproteinmuteine, peptide davon und damit im zusammenhang stehende verfahren
BR9710654A (pt) Proteinas trifoliadas intestinais
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
ATE364083T1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
FI962114L (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
NO974179L (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
DK0783585T3 (da) Defekte rekombinante adenovira med et inaktiveret IVa2-gen
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
NO951315L (no) Ökt produksjon av utsondrede proteiner fra rekombinante eukaryote-celler
ZA979390B (en) Polypeptides comprising domains of the GAX protein which are involved in the repression of transcription and/or which interact with other proteins, corresponding nucleic acids and their uses.
ATE84315T1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.
ES2181444T3 (es) Composicion para la induccion de una respuesta inmunologica especifica de un tumor, metodo para la produccion y utilizacion de dicha composicion en el tratamiento de neoplasias.
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0648271

Country of ref document: EP

REN Ceased due to non-payment of the annual fee